Stocks
Intra-Cellular Therapies, Inc.ITCI
NASDAQHealthcareBiotechnology$131.87+0.00%
Price as of · delayed, not real-time
Focused on developing novel drugs for neuropsychiatric and neurodegenerative disorders, this biopharma company's lead product targets schizophrenia and bipolar depression. Investors monitor its commercial execution and pipeline progress given the high unmet need in CNS therapeutics.
Market Cap: $14.0B52W Range: $64.09 – $131.98
Congressional Interest in Intra-Cellular Therapies, Inc. (ITCI)
3 members of Congress have disclosed 8 trades in Intra-Cellular Therapies, Inc. (ITCI), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 6 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
8
Unique Politicians
3
Buys
2
Sells
6
Who in Congress Is Trading ITCI?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-03 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-04-03 | Josh Gottheimer | sell | $1K – $15K |
| 2025-03-24 | Gilbert Cisneros | sell | $1K – $15K |
| 2025-03-17 | Josh Gottheimer | sell | $1K – $15K |
| 2025-01-24 | Josh Gottheimer | sell | $1K – $15K |
| 2024-06-21 | Josh Gottheimer | sell | $1K – $15K |
| 2021-12-21 | Josh Gottheimer | buy | $1K – $15K |
| 2017-05-01 | Roger W. Marshall | buy | $1K – $15K |